Verônica Silva Vilela1, Nilson Ramirez de Jesús, Roger Abramino Levy. Show Affiliations » 1. Division of Rheumatology, Faculdade de Cincias Medicas, Universidade do Estado do Rio de Janeiro, Brazil.
Abstract
Entities: Disease
Mesh： See more » Administration, OralAnticoagulants/administration & dosageAnticoagulants/adverse effectsAnticoagulants/therapeutic useAntiphospholipid Syndrome/complicationsAntiphospholipid Syndrome/drug therapyAspirin/administration & dosageAspirin/therapeutic useBlood Coagulation TestsBone Diseases, Metabolic/complicationsClinical Trials as TopicDrug Therapy, CombinationFemaleFetus/drug effectsFibrinolytic Agents/administration & dosageFibrinolytic Agents/adverse effectsFibrinolytic Agents/therapeutic useGestational AgeHeart Valve Prosthesis/adverse effectsHeparin/administration & dosageHeparin/adverse effectsHeparin/therapeutic useHeparin, Low-Molecular-Weight/administration & dosageHeparin, Low-Molecular-Weight/therapeutic useHumansInjections, SubcutaneousPlatelet Aggregation Inhibitors/administration & dosagePlatelet Aggregation Inhibitors/therapeutic usePregnancyPregnancy Complications, Cardiovascular/prevention & controlProspective StudiesPulmonary Embolism/prevention & controlRisk FactorsThrombocytopenia/chemically inducedThrombophilia/complicationsThrombophlebitis/prevention & controlThrombosis/prevention & controlTime FactorsWarfarin/administration & dosageWarfarin/adverse effectsWarfarin/therapeutic use
Substances： See more » AnticoagulantsFibrinolytic AgentsHeparin, Low-Molecular-WeightPlatelet Aggregation InhibitorsWarfarinHeparinAspirin
Year: 2002 PMID： 12389343
Source DB: PubMed Journal: Isr Med Assoc J Impact factor: 0.892